Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filedfiledCritical
Priority to ECSP003696priorityCriticalpatent/ECSP003696A/en
Publication of ECSP003696ApublicationCriticalpatent/ECSP003696A/en
Medicines That Contain Protein Lipid Enzymes And Other Medicines
(AREA)
Abstract
La presente invención proporciona métodos de tratamiento usando combinaciones sinergísticas de un antagonista de receptor de NK1 y un análogo de GABA y composicioones farmacéuticas y productos que contienen al antagonista de receptor de NK1 y el análogo de GABA. La p resente invención también proporciona el uso de una natgonista de receptor de NK1 y un análogo de GABA para la fabricación de un medicamento para el tratamiento o la prevención del dolor crónico.The present invention provides methods of treatment using synergistic combinations of an NK1 receptor antagonist and a GABA analog and pharmaceutical compositions and products containing the NK1 receptor antagonist and the GABA analog. The present invention also provides the use of a NK1 receptor natgonist and a GABA analog for the manufacture of a medicament for the treatment or prevention of chronic pain.
ECSP0036962000-10-062000-10-06
SYNTHETIC COMBINATIONS OF AN NK1 RECEIVER ANTAGONIST AND A GABA STRUCTURAL ANALOG
ECSP003696A
(en)
USE OF A PEPTIDE MIXTURE FOR THE MANUFACTURE OF A THERAPEUTIC AGENT FOR PROFILAXIS AND / OR CANCER TREATMENT, PHARMACEUTICAL COMPOSITIONS AND VACCINES CONTAINING SUCH MIXTURE AND THE PROCEDURES FOR PREPARATION OF THESE COMPOSITIONS
A COMPOSITION FOR THE TREATMENT OF EXTERNAL RETINA DISORDERS AND THE USE OF A GLUTAMATE ANTAGONIST FOR THE MANUFACTURE OF A MEDICINAL PRODUCT FOR THE TREATMENT OF EXTERNAL RETINA DISORDERS
SYNTHETIC COMBINATIONS OF AN NK1 RECEIVER ANTAGONIST AND A GABA STRUCTURAL ANALOG. (SYNERGISTIC COMBINATIONS OF A NKI RECEIVER ANTAGONIST AND A GABA STRUCTURAL ANALOG)
USE OF N- MONOHYDROCHLORIDE (ENDO-9-METHYL-9-AZABICICLO [3.3.1] NON-3-IL) -1- METHYLIMIDAZOLE-3-CARBOXAMIDE, FOR THE MANUFACTURE OF A MEDICINAL PRODUCT FOR THE TREATMENT OR PROPHYLAXIS OF DIARRHEA AND A PHARMACEUTICAL COMPOSITION THAT CONTAINS IT